Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Clinical Research Advantage Inc

Neither a doctor nor a teaching hospital

Research payments

$32,140,475

2,904 payments

Through program year 2025, Clinical Research Advantage Inc is reported as receiving $32,140,475 in research payments, across 2,904 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $10,605,614 415
2024 Research $192,769 82
2023 Research $2,954,410 454
2022 Research $4,964,506 267
2021 Research $9,452,070 440
2020 Research $1,391,973 378
2019 Research $2,579,133 868

Breakdown

Who paid Research payments · program years 2019–2025
  1. Sanofi Pasteur Inc. $26,581,717 1,538 payments
  2. AstraZeneca Pharmaceuticals LP $1,901,094 100 payments
  3. Allergan Inc. $1,889,638 529 payments
  4. Sanofi US Services Inc. $863,140 469 payments
  5. Kowa Research Institute, Inc. $302,418 160 payments
  6. AstraZeneca UK Limited $282,939 36 payments
  7. Amgen Inc. $217,567 17 payments
  8. Janssen Research & Development, LLC $35,962 23 payments
  9. Biogen, Inc. $23,063 4 payments
  10. Sunovion Pharmaceuticals Inc. $13,023 6 payments
Studies the money was for Research payments · program years 2019–2025
  1. Immunogenicity and Safety of SARS-CoV-2 Recombinant Protein Vaccines With AS03 Adjuvant in Adults 18 Years of Age and Older as a Primary Series and Immunogenicity and Safety of a Booster Dose of SARS-CoV-2 Adjuvanted Recombinant Protein Vaccines (Two Monovalent and One Bivalent) $5,889,531 381 payments
  2. A Phase 1/2, Parallel, Randomized, Modified Double-blind, Multi-arm Study to Assess the Safety and Immunogenicity of a Combination Vaccine Comprised of Different Recombinant Spike Antigen Levels of a Matrix-M Adjuvanted Recombinant COVID-19 Vaccine and High-dose Inactivated Influenza Vaccine in Adult Participants 50 Years of Age and Older $5,128,765 165 payments
  3. A Phase 1/2, Parallel, Randomized, Modified Double-blind, Multi-arm Study to Assess the Safety and Immunogenicity of a Combination Vaccine Comprised of Different Recombinant Spike Antigen Levels of a Matrix-M Adjuvanted Recombinant COVID-19 Vaccine and Recombinant Influenza Vaccine in Adult Participants 50 Years of Age and Older $4,867,144 139 payments
  4. A Parallel-group, Phase III, Multi-stage, Modified Double-blind, Multi-armed Study to Assess the Efficacy, Safety, and Immunogenicity of Two SARS-CoV-2 Adjuvanted Recombinant Protein Vaccines (Monovalent and Bivalent) for Prevention Against COVID-19 in Adults 18 Years of Age and Older $4,176,209 641 payments
  5. Study to Assess the Safety and Immunogenicity of Monovalent mRNA NA Vaccine in Adult Participants 18 Years of Age and Older $2,363,615 18 payments
  6. A Phase II, Open-label Study to Assess the Safety and Immunogenicity of Fluzone High-Dose Quadrivalent (Influenza Vaccine), 2021-2022 Formulation and a Third Dose of Moderna COVID-19 Vaccine (mRNA-1273 Vaccine) Administered Either Concomitantly or Singly in Adults 65 Years of Age and Older Previously Vaccinated With a 2-dose Schedule of Moderna COVID-19 Vaccine $1,645,840 61 payments
  7. Safety and Immunogenicity of Quadrivalent Recombinant Influenza Vaccine Formulations Containing Different H3 Hemagglutinin Antigens Without or With Adjuvant in Healthy Adult Subjects $1,393,582 25 payments
  8. A Phase III Randomized Double-blind Placebo-controlled Multi-center Study in Adults to Determine the Safety and Efficacy of AZD7442 a Combination Product of Two Monoclonal Antibodies (AZD8895 and AZD1061) for Pre-exposure Prophylaxis of COVID-19 $1,194,261 6 payments
  9. A Long Term Outcomes Study to Assess STatin Residual Risk Reduction with EpaNova in HiGh Cardiovascular Risk PatienTs with Hypertriglyceridemia $736,038 96 payments
  10. A Phase I, parallel, randomized, active-controlled, multi-center, dose-escalation study with early safety data reviews to assess safety and immunogenicity of a monovalent mRNA vaccine encoding influenza hemagglutinin in adults 18 years of age and older $659,552 28 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record